• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The present invention relates to a composition containing cholestyramine as a substance which absorbs and / or eliminates bacterial toxins for use in the prevention and / or treatment of inflammatory conditions and / or diseases of the mucous membranes, in particular in the oral cavity, through the adsorption and / or elimination of bacterial Toxins, in particular bacterial lipopolysaccharides (LPS) and / or lipoteichoic acids (LTA). The invention also relates to a dosage form and a toothpaste.
    公开号:AT16944U1
    申请号:TGM9005/2017U
    申请日:2017-04-07
    公开日:2020-12-15
    发明作者:Seidel Dietrich
    申请人:Seidel Dietrich；
    IPC主号:
    专利说明:

    description
    PRODUCTS FOR USE IN INFLAMMATORY CONDITIONS OF THE MUCCOUS
    The present invention relates to a composition for use in the prevention and / or treatment of inflammatory conditions and / or diseases of mucous membranes, in particular in the area of the oral cavity.
    The oral cavity represents the beginning of the digestive tract. It is lined with a mucous membrane, the so-called oral mucosa, and is colonized by a large number of microorganisms, which offer favorable living conditions there. On the one hand, the oral cavity is a space with a constant and relatively high temperature, which is also characterized by high humidity. On the other hand, food is taken up via the oral cavity, which means that there is a continuous supply of nutrients in this space. Due to the presence of hard-to-reach bottlenecks, e.g. Between the teeth, food debris can accumulate, which is a favorable breeding ground for microbial growth. The oral cavity thus offers suitable conditions for microorganisms to multiply.
    In a healthy person, the microflora of the oral cavity is in a natural balance. Normally there is neither an excessive reproduction of certain species of microorganisms nor a colonization by external pathogenic microorganisms. In cases in which the oral mucosa can no longer fulfill its natural barrier function, e.g. As a result of injuries or as a result of inflammation of the oral mucosa, microorganisms can come into contact with deeper-lying tissue and initially cause an infection, usually local. As a result, the organism's defense mechanisms are set in motion or strengthened, and an initially mostly local inflammatory reaction occurs. This can extend to adjacent tissue and also lead to chronic inflammatory conditions. In unfavorable cases, such a local infection can even spread systemically. A connection is also known between infections of the oral cavity with the simultaneous development of atherosclerosis or an increased risk of heart attack, rheumatic diseases or diabetes mellitus.
    [0004] A favorable factor for inflammatory diseases of the oral cavity is increased plaque. This is caused, for example, by the accumulation of food residues in places that are less exposed to mechanical abrasion when chewing or cleaning teeth. As a result, there is increased growth of bacteria there, which enables the formation of bacterial biofilms. The accumulation of minerals can calcify the plaque into tartar.
    The settlement of bacteria in the area of the dental plaque causes a wide variety of bacterial metabolism and degradation products to be released. The presence of such substances is a warning of possible infection. The immune system of the colonized organism is able to perceive these indications and initiate an appropriate defense reaction. For this purpose, cells of the colonized organism can register the presence of these bacterial products by means of specific receptors on the cell surface. The warning is then passed on in the organism via various cellular signaling pathways and corresponding cytokines, and specialized immune cells are recruited to fight the infectious agents. For example, some immune cells can release certain chemicals and enzymes that are able to destroy bacteria.
    [0006] Periodontal diseases, inter alia, are known as inflammatory diseases of the oral cavity. This includes, for example, inflammation of the tooth holding apparatus (periodontium), which is referred to as periodontitis, or inflammation of the gums (gingivitis). In general, a distinction is made in periodontitis between marginal periodontitis, which starts from the gum line, and apical periodontitis, which starts from the tip of the tooth. The prophylaxis and treatment of all these diseases represents an important area of the
    Dentistry.
    According to the current classification of periodontal diseases, this term includes gingival diseases, chronic periodontitis, aggressive periodontitis, periodontitis as a manifestation of systemic diseases, necrotizing periodontal diseases, abscesses of the periodontium, periodontitis in connection with endodontic lesions and developmental or acquired deformations.
    [0008] In the course of periodontal diseases, an inflammatory reaction that can be traced back to bacteria usually spreads to several or even all parts of the periodontium. This leads to tissue destruction and degradation of the periodontium.
    [0009] Marginal periodontitis, for example, is an infection with specific, strictly anaerobic or microaerophilic pathogens, which is typically chronically recurrent. The most important periodontitis-causing pathogens are: Porphyromonas gingivalis, Tannerella forsythia, Aggregatibacter actinomycetemcomitans, all gram-negative pathogens. These bacteria are also known as periodontal marker bacteria. One consequence of such chronic infections is the slow loss of the connective tissue holding apparatus of the tooth (so-called attachment loss), and with long-term progression of the disease also the loss of the osseous tooth holding apparatus of the jaw-alveolar bone.
    The periodontium is, probably due to the continuous contact with microorganisms, an immunologically very reactive tissue that responds strongly to the release of bacterial products of the periodontal pathogen. This explains that in periodontal diseases, unlike infections in other compartments of the body, tissue destruction is mainly caused by the body's own immune reaction. This includes the breakdown of connective tissue by enzymes released by immune cells such as Metalloproteinases and bone breakdown through activation of osteoclasts, which is promoted by prostaglandins and TNFalpha as well as some interleukins.
    In addition, the periodontal marker bacteria also produce virulence factors that favor their tissue invasiveness and thus lead to a local intensification of the inflammatory reaction. The body's own mechanisms, such as GCitrullination of proteins, further promote the immune reaction, which in turn increases cell loss on the part of the affected individual.
    As a prophylaxis for periodontal diseases, in addition to domestic oral hygiene, the implementation of professional teeth cleaning is recommended, which serves to remove existing plaque and / or tartar as completely as possible in order to keep or avoid an inflammation-promoting activation of the immune system within physiological limits.
    In dentistry, periodontal diseases are treated according to several approaches. The cleaning of the tooth root and the tooth enamel from plaque by mechanical methods, also by means of ultrasound and laser application, is of great importance. Furthermore, antiseptics such as e.g. Chlorhexidine can be introduced into the gingival sulcus using a blunt cannula or paper carriers (Periochip®). Furthermore, antibiotics such as e.g. Minocycline can be introduced into the gingival sulcus. It is often introduced using a carrier material that is slowly broken down and releases the active ingredient evenly over this period of time.
    For a long-term success of the treatment, the methods described must be carried out repeatedly. However, since these methods, especially those based on mechanical cleaning, are sometimes painful, the willingness of patients to enable these regular repetitions is often not particularly high, which reduces the success of the treatment.
    [0015] The antiseptic or antibiotic treatment carried out in certain cases in parallel to the removal of plaque and / or tartar does not specifically target the pathogens that are the cause of the periodontal disease, but mostly damage the entire oral cavity.
    flora. As a result, on the one hand, the balance of the oral flora can be damaged, so that certain microorganisms that are resistant to an antibiotic multiply. This can encourage further infections. On the other hand, the use of antibiotics, and especially long-term use, can lead to resistance on the part of microorganisms, which is currently one of the greatest threats to public health. In addition, by killing bacteria with antibiotics, bacterial products, especially degradation products (bacterial toxins), are released which further intensify the body's own immune reaction and, under certain circumstances, tissue destruction and have a lasting negative effect on the physiological environment.
    [0016] It was therefore the object of the present invention to provide improved possibilities for the prevention and / or treatment of inflammatory conditions and / or diseases of the oral cavity that are in particular gentle on the patient.
    This object is achieved by providing a composition which adsorbs bacterial products, preferably bacterial toxins, in the context of the prevention and / or treatment of inflammatory conditions and / or diseases of the oral cavity. According to the invention, the composition contains the substance colestyramine (poly (trimethylammoniomethylstyrene chloride-co-divinylbenzene), which has anion exchanger groups. These are suitable for bacterial products, in particular toxic bacterial products such as lipopolysaccharides (LPS) or / and lipoteichonic acids (LTA) to adsorb.
    As a result of this adsorption, on the one hand, diffusion of the toxic bacterial products from the focus of inflammation into adjacent areas is prevented. On the other hand, the adsorption reduces the amount of toxic bacterial products present in solution. This creates a prerequisite for establishing the physiological environment in the inflammation area and promotes and ensures a normal immune reaction.
    The present invention thus provides possibilities of neutralizing pro-inflammatory bacterial products, in particular LPS and LTA, by binding. In the absence of such adsorption or neutralization, there is an increase in the concentration of the toxic bacterial products present in solution, which, through further activation of the immune system, leads to an intensification of tissue destruction. Such a treatment approach has not yet been followed in periodontics.
    Furthermore, it was found that it is also possible to remove the toxic bacterial products from the site of inflammation, in addition to adsorption or neutralization, by removing the cholestyramine or the cholestyramine-containing composition after use at the site of inflammation.
    The adsorption or neutralization and / or removal of the toxic bacterial products from the site of inflammation generally improves the conditions for natural regeneration processes. Furthermore, such a procedure brings about a consistent down-regulation of the local immune reaction and thus leads to a significant reduction in tissue destruction, in particular through the body's own mechanisms. This is of great importance especially for the treatment of periodontal diseases, since the connective tissue supporting the teeth is difficult to regenerate after damage.
    In general, the composition used according to the invention can be used alone or in combination with known preventive or treatment methods. The use according to the invention of the adsorbent colestyramine is painless for the patient, for example in contrast to mechanical cleaning, and no side effects are to be expected. The substance has been known and widely used in medicine for lowering blood cholesterol and binding bile salts in the intestine for more than 40 years. Regular use has a positive effect on the general success of the treatment and as a result the duration of treatment can be reduced compared to the duration of a treatment which is based exclusively on known treatment methods. It is assumed that these factors help ensure that patients can rely on an from
    attending physician adhere to the prescribed therapy regimen. The provision of the composition for the treatment of diseases, in particular periodontal diseases, thus also improves patient compliance.
    Furthermore, when using the adsorbent according to the invention, it can be avoided that a massive, local release of toxic bacterial products leads to the transfer of these products into the bloodstream and thus into the entire body of the patient. This process can trigger the well-known sequential cascade, which progresses partially autoimmune-destructively via the activation of mediators and can lead to septic manifestations up to septic shock and death of the patient.
    It is now generally recognized that a connection, at least a partial connection, between periodontosis and atherosclerosis, especially coronary heart disease (CHD) and the incidence of myocardial infarction, is also based on the generalization and chronification of inflammations in the mouth and teeth. Periodontal disease patients have a 25% higher risk of CHD than those with healthy teeth. The mortality of CHD patients is also two times higher in the presence of periodontal disease compared to healthy teeth.
    [0025] Proinflammatory and prothrombotic inflammation mediators, which are increasingly washed into the bloodstream as a result of a locally increased bacterial toxin load, can act as a link between chronic inflammation in the dental area and the CAD. There they can stimulate and maintain essential vascular-atherogenic processes, which will ultimately lead to the closure of an artery. Preliminary results exist which indicate that the remediation of chronic inflammation sources (e.g. periodontal disease) also leads to the normalization of increased inflammation mediators in the blood and tissue, increases the efficiency of statin therapy for lowering LDL and allows a reduction in the amount of insulin required in the treatment of diabetes mellitus .
    It is therefore to be expected that the use according to the invention of LPS and LTA adsorbent material in the oral area will also lead, inter alia, to a reduction in the heart attack rate in the population.
    It was also found that the inventive use of the adsorbent does not interfere with the physiological defense and repair mechanisms of the organism. Through the use according to the invention, the harmful bacterial products are removed in an extremely effective manner, but the physiological environment at the site of inflammation, especially with regard to the concentration ratios of the body's own mediators and cytokines, is normalized to such an extent that the physiological healing processes can proceed undisturbed.
    In general, an inflammatory condition of the oral cavity which can be treated according to the present invention can result from an infection or an injury to the oral mucosa. Not only representatives of the natural oral flora come into question here as infectious agents, but also any microorganisms taken up from the environment through the mouth opening.
    In one embodiment, the inflammatory condition of the oral cavity results from infection with bacteria. In a preferred embodiment, it is an infection with gram-negative bacteria and / or gram-positive bacteria. In a particularly preferred embodiment, it is an infection with one or more bacteria selected from the group consisting of Porphyromonas gingivalis, Tannerella forsythia, Aggregatibacter actinomycetemcomitans.
    The development of a chronic infection on site can also be favored by injuries to the oral mucosa, be it during the chewing process or as a result of any injuries, even during operations, in the case of a general weak immune system.
    In one embodiment, the disease of the oral cavity is periodontal disease. In a preferred embodiment, the periodontal disease is marginal periodontitis.
    In a particularly preferred embodiment, the periodontal disease is selected from the group consisting of gingival diseases, chronic periodontitis, aggressive periodontitis, periodontitis as a manifestation of systemic diseases, necrotizing periodontal diseases, abscesses of the periodontium, periodontitis in connection with endodontic lesions and / or development-related or acquired deformations and states. The agent used according to the invention for adsorbing bacterial products, in particular toxic bacterial products such as e.g. LPS and LTA, has anion exchanger groupings. These are able to selectively and effectively bind LPS and LTA and thus absorb, neutralize and, if necessary, even enable their removal at the site of inflammation.
    It is advantageous if good wetting of the LPS and / or LTA-adsorbing cholestyramine is ensured at the point of use and it has the largest possible surface area when used. Colestyramine, which is already used to treat hypercholesterolemia, binding of bile acids in the intestine and also for chologener diarrhea, is available as a substance in the form of a fine hygroscopic powder. It is an enzymatically non-decomposable, water-insoluble macromolecule, which has been known in conventional medicine for over 40 years, is not absorbable in the intestine and is therefore not metabolized. It is currently available in the form of granules, powder or chewable tablets for oral intake.
    It is also possible to use the cholestyramine present in the composition according to the invention in combination with one or more other active ingredients. There are no limitations whatsoever with regard to the selection of such additional active ingredients. A person skilled in the art can combine any further active ingredients with the adsorbent used according to the invention, as long as the intended effectiveness of the adsorbent is not impaired thereby in such a way that the adsorption of toxic bacterial products provided according to the invention is prevented.
    In a preferred embodiment, the one or more further active ingredients is selected from the group consisting of antibacterial active ingredients, anti-inflammatory active ingredients, pain-relieving active ingredients, regenerative active ingredients or mixtures thereof. Antibiotics, silver ions, zinc oxide, povidone iodine, activated charcoal, ibuprofen, acetylsalicylic acid, diclofenac, local anesthetics such as e.g. Lidocaine or benzocaine, dexpanthenol, or mixtures thereof.
    [0035] Conventional therapy of inflammatory conditions and / or diseases of the oral cavity often includes at least a supportive antibiotic or antiseptic treatment. Antibiotic treatment usually does not work selectively against the pathogenic microorganisms that cause the disease to be treated, but also against the natural oral flora. Damage to the natural balance of the oral flora, which is normally present in the oral cavity, can in turn have negative effects on the success of the therapy, for example by favoring infections by opportunistic pathogens. Furthermore, with antibiotic treatments there is generally the problem of the development of resistance, which can jeopardize the success of the therapy. Nevertheless, in the conventional treatment of inflammatory conditions and / or diseases of the oral cavity, it is often necessary to use antibiotics or other antibacterial agents in order to support the body's immune system in combating disease-causing bacterial colonization.
    In the context of the present invention, the inventive use of cholestyramine by lowering the toxin load often makes it possible to dispense with the use of antibiotics or other antibacterial agents, or to largely reduce their use.
    The use according to the invention of a composition containing cholestyramine supports the body's own immune system. Under certain conditions, it is also conceivable, for example, that by neutralizing immune-activating bacterial products, the death of immune cells can be reduced and in this way more immune cells are available to fight the bacterial pathogens. With such support
    the immune system is enabled to better control the bacterial infection (increased toxin load) and to at least reduce the administration of antibiotics and / or other antibacterial agents in the treatment of an inflammatory condition and / or a disease of the oral cavity.
    It may also be possible to completely dispense with the supporting use of antibiotics if the attending physician realizes that mechanical cleaning and / or use of the composition according to the invention are sufficient to achieve sufficient treatment success.
    By dispensing with the use of antibiotics and / or reducing their use, it is possible to overcome or reduce the adverse effects of these treatment options. In particular, the cholestyramine used according to the invention neither adversely affects the balance of the oral flora, nor does it promote the development of antibiotic resistance by bacteria. In this connection it should be noted in particular that a development of resistance to the neutralization of toxic bacterial products according to the invention cannot be expected.
    In another embodiment of the present invention and insofar as this appears necessary, colestyramine in combination with an antibiotic and / or antibacterial agents can be used in the composition. In the context of the present invention, it was found that the treatment of inflammatory diseases of the oral cavity can also be positively influenced by such a procedure.
    The targeted killing of bacteria helps to combat the cause of inflammation, but also leads to a massive release of toxic bacterial products, especially when using bactericidal agents. These bacterial products in turn strengthen the body's own mechanisms underlying tissue destruction. Quite in contrast to the previous situation, the composition used according to the invention can neutralize these bacterial products before the immune system can be (over) activated. In this way it can be avoided that increased tissue destruction occurs and / or that the healing process is negatively influenced in some other way by the release of toxic bacterial products as a result of antibiosis. Furthermore, it can be avoided that the toxic bacterial products enter the bloodstream and cause adverse systemic effects up to septic shock or, in the chronic course, lead to accelerated atherosclerosis, heart attack, diabetes mellitus or other diseases with an inflammatory component.
    The combination of cholestyramine with antibacterial agents is particularly advantageous when using bactericidal agents and / or when there is a high bacterial density, as is the case with periodontal diseases.
    The composition used according to the invention can also be combined with products that are used for the care, cleaning and / or treatment of the oral cavity. For example, the cholestyramine can be used as an additive in tooth cleaning products such as e.g. Toothpaste or tooth gel can be used.
    Due to the function of the salivary glands, the oral cavity has a constantly moist environment, the surface of the oral cavity, in particular the oral mucosa and tooth surfaces, usually being constantly covered by a thin film of liquid. In the case of a local application of therapeutic agents in the oral cavity, the problem generally arises that these are removed again from the application site after application due to this liquid film and mechanical friction which is generated by mouth movements. The resulting problem of inadequate dwell time of the applied agent at the respective area to be treated can also exist with the use of cholestyramine according to the invention.
    This problem can be overcome in that the composition used according to the invention is used in a form which is adherent to the mucous membrane. This can
    can preferably be achieved by using a composition with a thick, paste-like or gel-like consistency. It is also possible that such a consistency arises only when the composition is wetted. Such wetting can take place through fluid present in the oral cavity, but also through fluid to be applied from the outside.
    In a particularly preferred embodiment, the composition of the invention comprises a gelling agent or a gel base. Such gelling agents can be selected from the group consisting of alginates, polyacrylic acid, carboxymethyl cellulose, gum tragacanth, silicon dioxide, gelatin, methyl cellulose, poloxamers or povidone, but are not limited thereto. Further aids suitable for this purpose are known to the person skilled in the art, for example from standard works such as “Remington's Pharmaceutical Sciences”.
    The use of the compositions described above, especially in the oral cavity, is particularly advantageous, since the described adhesiveness is due to the spatial confinement of certain application areas, e.g. in interdental spaces or gum pockets, is reinforced. In this way, a further increased residence time of the cholestyramine can be achieved there. These areas of application are of particular interest in the case of periodontal diseases. The dental plaque that triggers the disease also preferably forms at these points.
    The composition according to the invention is preferably provided in a dosage form which is selected from the group consisting of a paste such as e.g. a toothpaste, a gel such as e.g. a tooth gel or a sprayable liquid such as e.g. a spray. Provision using other materials such as hollow fibers, membranes, flat membranes, sponges, filter materials, particles, porous particles, beads, granules or powders, to which colestyramine is applied or with which it is mixed, is also possible. These dosage forms can be provided in a wide variety of applicators, depending on the consistency, for example in dispensers or spray dispensers, e.g. a spray can or a powder sprayer. It is also possible to provide them in insert pads which are suitable for use in the mucous membrane area, such pads e.g. can also be inserted into gum pockets.
    In a preferred embodiment, the composition according to the present invention comprises cholestyramine in a concentration of 5% by weight to 50% by weight, preferably of 5% by weight to 40% by weight or of 15% by weight % to 40% by weight, or more preferably from about 15% by weight, each based on the total weight of the composition.
    Compositions according to the present invention can further comprise any known additional carrier materials and excipients.
    According to the present invention, the composition according to the invention can be used in the mucous membrane area, in particular in the oral cavity, but also in other body areas. Use on the gums and / or the gingival margin or the gingival sulcus is particularly preferred. An introduction into hard-to-reach places in the oral cavity, e.g. Periodontal pockets or between the teeth.
    The composition according to the invention can be used before, during and / or after other treatment methods.
    In addition to being used for therapeutic purposes, the composition according to the invention can also be used prophylactically. The application can be carried out by the attending physician and / or the patient.
    When using certain embodiments of the composition, it is not even necessary to remove them again via the mouth opening, for. B. by rinsing. Removal can also be done through the digestive system. For this it is advantageous that cholestyramine is sufficiently inert for the gastrointestinal tract and is not absorbed, which guarantees its very good biocompatibility.
    When using any of the above-described configuration of the composition, in particular when using particles, porous particles, granules, powders, beads, membranes or hollow fibers, it is also possible to put the adsorbent or the pharmaceutical composition used according to the invention in small bags or bags to provide packed. It must be ensured here that a material is used for the manufacture of such bags or pouches which is sufficiently permeable for the bacterial products to be removed, but which prevents the adsorbent from escaping. Such pouches or pouches can be suitably sized depending on the needs of the use. For example, bags or pouches of a size can be used that can be inserted into narrow spaces in the oral cavity, for example interdental spaces or gingival pockets, by the attending physician. The pouches or pouches can be left in place for a sufficient time to allow binding of the toxic bacterial products. The attending physician can then remove the bags or pouches, which also removes the toxic bacterial products that have been adsorbed in the meantime from the treatment site. The same applies if the composition, as described above, is used in a different configuration, for example in a combination of a membrane or pads of any kind. In addition to use in human medicine, use in veterinary medicine is also provided.
    The specific configuration of the composition according to the invention for use in the oral cavity is within the ability of the person skilled in the art; however, colestyramine can be integrated particularly easily into a toothpaste which can be used preventively or therapeutically in daily oral hygiene. Such a toothpaste, which contains cholestyramine as an active ingredient, optionally in combination with other active ingredients, is therefore a further subject of the present invention.
    The indicated possibilities of using the agents and compositions according to the invention in the area of the oral cavity, in particular on the oral mucosa, can be transferred in particular to applications in the female vaginal area. Also there is u. a. a similarly moist environment as in the oral cavity and infections or infected mucosal injuries are not as easily accessible as would be the case with superficial wounds.
    A further field of application of the present invention is therefore its use in the prevention or, in particular, treatment of inflammatory conditions or diseases of the vaginal mucosa.
    权利要求:
    Claims (11)
    [1]
    1. Composition containing cholestyramine as a bacterial toxin absorbing and / or eliminating substance for use in the prevention and / or treatment of inflammatory conditions and / or diseases of the mucous membranes, especially in the oral cavity, by adsorption or / and elimination of bacterial toxins, in particular bacterial lipopolysaccharides (LPS) and / or lipoteichoic acids (LTA).
    [2]
    2. Composition according to claim 1, characterized in that the inflammatory condition of the oral cavity results from an infection or an injury to the oral mucosa, or that the inflammatory disease of the oral cavity is a periodontal disease.
    [3]
    3. Composition according to claim 2, characterized in that the periodontal disease is selected from gingival diseases, chronic periodontitis, aggressive periodontitis, periodontitis as a manifestation of systemic diseases, necrotizing periodontal diseases, abscesses of the periodontium, periodontitis in connection with endodontic lesions and development-related or acquired deformations and States.
    [4]
    4. Composition according to one of claims 1 to 3, characterized in that it is adhesive to the oral mucosa.
    [5]
    5. Composition according to claim 4, characterized in that the composition has a thick, paste-like or gel-like consistency.
    [6]
    6. Composition according to claim 4 or 5, characterized in that the pharmaceutical composition comprises a gelling agent.
    [7]
    7. Composition according to claim 6, characterized in that the gelling agent is selected from the group consisting of alginates, polyacrylic acid, carboxymethyl cellulose, gum tragacanth, silicon dioxide, gelatin, methyl cellulose, poloxamers or povidone.
    [8]
    8. Composition according to one of claims 1 to 7, characterized in that it contains one or more further active ingredients, wherein the one or more further active ingredients are selected from the group consisting of antibacterial active ingredients, anti-inflammatory active ingredients, pain relieving active ingredients, regenerative active ingredients or mixtures thereof.
    [9]
    9. Composition according to one of claims 1 to 7, characterized in that it contains one or more further active ingredients, wherein the one or more further active ingredients are selected from the group consisting of an antibiotic, silver ions, zinc oxide, povidone iodine, activated carbon, Ibuprofen, acetylsalicylic acid, diclofenac, a local anesthetic such as lidocaine or benzocaine, dexpanthenol and mixtures thereof.
    [10]
    10. A dosage form containing a composition according to any one of claims 1 to 10, characterized in that the dosage form is selected from the group consisting of a paste, a gel or a sprayable liquid.
    [11]
    11. Toothpaste, characterized in that it has cholestyramine as an active ingredient.
    No drawings for this
    类似技术:
    公开号 | 公开日 | 专利标题
    Abbott1990|Medicaments: aids to success in endodontics. Part 1. A review of the literature
    Kennedy et al.2007|The antimicrobial effects of root canal irrigation and medication
    EP1917982B1|2010-04-21|Product for the treatment of inflammation, bruises and/or ulcers in the oral area and the use of such a product
    DE10337340B4|2021-07-22|composition
    PL205148B1|2010-03-31|Use of chemotherapeutic agents for topical treatment
    US20120189710A1|2012-07-26|Antibacterial compositions
    AT15430U1|2017-08-15|Dental agent based on hyaluronan and octenidine dihydrochloride
    CN101347388A|2009-01-21|Oral cavity nursing agent and preparation technique thereof
    Agrawal et al.2013|An in vitro comparison of antimicrobial effcacy of three root canal irrigants-BioPure MTAD, 2% chlorhexidine gluconate and 5.25% sodium hypochlorite as a final rinse against E. faecalis
    EP0450117A1|1991-10-09|Ringers solution and its use as a bactericidally active local wound-treatment medicament
    AT16944U1|2020-12-15|Preparations for use in inflammatory conditions of the mucous membranes
    KR100573206B1|2006-04-28|Use of dichlorobenzyl alcohol for preparing a preparation for topical treatment of inflammation and a preparation containing dichlorobenzyl alcohol
    RU2482859C1|2013-05-27|Method of treating periodontitis and inflammatory diseases of oral mucosa
    CN1367018A|2002-09-04|Compound preparation of staphylococcolysis enzyme and its preparation method and application
    RU2712085C1|2020-01-24|Oral care means
    AT11910U1|2011-07-15|COMPOSITION CONTAINING CHLOROHEXIDINE, A BISPHOSPHONATE AND A NSAID
    US11278566B2|2022-03-22|Agent for use for inflammatory conditions of mucous membranes
    Ambikathanaya2014|Intracanal antiseptic medications; A Review
    EP3134075B1|2017-08-16|Oral delivery system
    RU2628806C1|2017-08-22|Method for chronic generalised periodontitis treatment
    CN1050758C|2000-03-29|Traditional Chinese medicine sterilizing agent and its preparing method
    Lorena et al.2021|REVIEW OF ENDODONTIC DRUGS AND THEIR ANTIBACTERIAL EFFECTIVENESS
    Adel et al.2016|Comparing the antimicrobial efficacy of carvacrol, chlorhexidine and calcium hydroxide on enterococcus faecalis in root canal treatment: an in vitro study
    Kaur et al.2018|Comparative Evaluation of Antimicrobial Efficacy of Chlorhexidine, Triphala Solution And Distilled Water When Used As An Irrigant In Canals Infected With Enterococcus Faecalis: An In Vitro Study
    RU2604128C1|2016-12-10|Preparation for treating periodontitis
    同族专利:
    公开号 | 公开日
    RU2741593C2|2021-01-27|
    DE202017006902U1|2018-10-08|
    EP3439627A1|2019-02-13|
    WO2017174796A1|2017-10-12|
    RU2018139188A3|2020-05-25|
    DE102016205950A1|2017-10-12|
    US20190125783A1|2019-05-02|
    RU2018139188A|2020-05-12|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    SU825074A1|1978-11-03|1981-04-30|Urusov Kazim Kh|Composition for treating parodontosis|
    WO1998030191A1|1997-01-07|1998-07-16|Sociedad Limitada Para El Desarrollo Cientifico Aplicado|Material intended to remineralise organomineral tissues|
    WO1999015186A1|1997-09-19|1999-04-01|Geltex Pharmaceuticals, Inc.|Cationic polymers as toxin-binding agents|
    US20140271491A1|2013-03-15|2014-09-18|Cook Medical Technologies Llc|Adhesive medical products and methods for treating gastrointestinal lesions|
    GB2021949B|1978-05-31|1982-11-17|Nicholas Pty Ltd|Inhibition of dental caries|
    DE2920071A1|1979-05-18|1980-11-20|Albers Hans K|Oral hygiene prepn. contg. acetyl:salicylic acid - for treatment of inflammatory diseases of the gums|
    US4725576A|1983-12-29|1988-02-16|Research Foundation Of State University Of New York|Fungicidal polypeptide compositions containing L-histidine and methods for use therefore|
    US5116603A|1989-01-31|1992-05-26|Yissum Research Development Company Of The Hebrew University Of Jerusalem|Oral antifungal preventative, and method of use|
    DE3930206A1|1989-09-09|1991-03-14|Knoll Ag|Hypolipaemic pharmaceutical prods. - comprising combination of cholestyramine and drug of vibrate type|
    US5053133A|1990-02-09|1991-10-01|Elias Klein|Affinity separation with activated polyamide microporous membranes|
    DE4435612A1|1994-10-05|1996-04-11|Braun Melsungen Ag|Process for the simultaneous removal of tumor necrosis factor alpha and bacterial lipopolysaccharides from an aqueous liquid|
    DE19501726A1|1995-01-20|1996-07-25|Merck Patent Gmbh|Polymerizable derivatives of polyamides|
    JPH11503005A|1995-03-08|1999-03-23|アクゾノーベルナムローゼフェンノートシャップ|Surface-modified affinity separation membrane|
    US5961958A|1996-07-16|1999-10-05|Four Star Partners|Methods, compositions, and dental delivery systems for the protection of the surfaces of teeth|
    DE29908415U1|1999-05-18|1999-07-22|Carl|Agents for the treatment of local periodontal infections|
    JP3893030B2|2001-04-18|2007-03-14|独立行政法人科学技術振興機構|Bacterial endotoxin adsorbent and screening method thereof|
    WO2005115417A2|2004-05-03|2005-12-08|Neosil, Inc.|Polycationic antimicrobial therapeutic|
    AT356643T|2004-06-03|2007-04-15|Braun Medizintechnologie Gmbh|DEVICE FOR REMOVING BACTERIAL LIPOPOLYSACCHARIDES AND / OR LIPOTEIC ACIDS FROM PROTEIN-CONTAINING LIQUIDS, AND USE THEREOF FOR THE PRODUCTION OF A MEANS FOR THE REMOVAL OF SUCH SUBSTANCES|
    US20080152724A1|2006-12-21|2008-06-26|Mark Hirsh|Treatment of periodontitis with an injectable slow release iodine|
    SG175785A1|2009-05-18|2011-12-29|Colgate Palmolive Co|Oral compositions containing polyguanidinium compounds and methods of manufacture and use thereof|
    DE102011005449A1|2011-03-11|2012-09-13|Sebo Gmbh|Products for bacterial toxin binding and elimination in the treatment of local infections and their production|
    DE202014009184U1|2014-11-19|2014-12-18|März Verwaltungs GmbH|Gel for the oral cavity|CN109985022B|2019-03-15|2021-03-23|哈尔滨天霖健生物工程有限公司|Povidone iodine preparation and its preparing method and use|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    DE102016205950.5A|DE102016205950A1|2016-04-08|2016-04-08|Means for use in inflammatory conditions of the mucous membranes|
    PCT/EP2017/058429|WO2017174796A1|2016-04-08|2017-04-07|Agent for use for inflammatory conditions of mucous membranes|
    [返回顶部]